DK0555135T3 - Process for the preparation of very high purity fibrinogen, thus produced very high purity fibrinogen, and a pharmaceutical composition containing it - Google Patents

Process for the preparation of very high purity fibrinogen, thus produced very high purity fibrinogen, and a pharmaceutical composition containing it

Info

Publication number
DK0555135T3
DK0555135T3 DK93400247.8T DK93400247T DK0555135T3 DK 0555135 T3 DK0555135 T3 DK 0555135T3 DK 93400247 T DK93400247 T DK 93400247T DK 0555135 T3 DK0555135 T3 DK 0555135T3
Authority
DK
Denmark
Prior art keywords
fibrinogen
high purity
solution
ionic strength
agarose
Prior art date
Application number
DK93400247.8T
Other languages
Danish (da)
Inventor
Mohamed Hamsany
Gerard Vezon
Bernard Dazey
Sylvia Enfedaque-Morer
Original Assignee
Ass Daquitaine Pour Le Dev De
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ass Daquitaine Pour Le Dev De filed Critical Ass Daquitaine Pour Le Dev De
Application granted granted Critical
Publication of DK0555135T3 publication Critical patent/DK0555135T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

The invention relates to a process for preparing fibrinogen of high purity. This process is characterised in that it comprises, starting with cryoprecipitates from blood plasma of animal or human origin, placed in aqueous solution, treating this solution so as to bring it to an ionic strength equal to that of a buffer solution having the following composition: NaCl 120 mM Tris 20 mM pH 8.8 this solution, of adjusted ionic strength, is passed through an anion exchange column comprising an anion exchange gel, for example in the form of beads, based on crosslinked agarose comprising quaternary amine groups, especially at the end of a small spacer arm, for example of the C1-C6-alkylene type linked to the agarose beads, in particular containing about 6% agarose and an elution is carried out using a first eluting solution of the same ionic strength, these conditions making it possible to adsorb at least selectively the fibrinogen onto the said column, which fibrinogen is desorbed using an eluting solution of higher ionic strength at 200 mM NaCl. A fibrinogen of high purity is obtained.
DK93400247.8T 1992-02-04 1993-02-02 Process for the preparation of very high purity fibrinogen, thus produced very high purity fibrinogen, and a pharmaceutical composition containing it DK0555135T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9201238A FR2686883B1 (en) 1992-02-04 1992-02-04 PROCESS FOR THE MANUFACTURE OF VERY HIGH PURITY FIBRINOGEN, VERY HIGH PURITY FIBRINOGENE, OBTAINED AS WELL AS A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME.

Publications (1)

Publication Number Publication Date
DK0555135T3 true DK0555135T3 (en) 1996-11-25

Family

ID=9426316

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93400247.8T DK0555135T3 (en) 1992-02-04 1993-02-02 Process for the preparation of very high purity fibrinogen, thus produced very high purity fibrinogen, and a pharmaceutical composition containing it

Country Status (7)

Country Link
EP (1) EP0555135B1 (en)
AT (1) ATE141284T1 (en)
DE (2) DE69303941T2 (en)
DK (1) DK0555135T3 (en)
ES (1) ES2049701T3 (en)
FR (1) FR2686883B1 (en)
GR (2) GR930300095T1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0602173B1 (en) * 1991-09-05 1999-05-26 Baxter International Inc. Topical fibrinogen complex
CA2195127C (en) * 1994-07-14 2007-06-19 Ruth Laub Concentrate of fibrinogene obtained from blood plasma, process and plant for its preparation
DE10261126A1 (en) * 2002-08-13 2004-03-04 Aventis Behring Gmbh Storage-stable, liquid fibrinogen formulation
DE102004009400A1 (en) 2004-02-24 2005-09-08 Zlb Behring Gmbh Fibrinogen purification
FR2887883B1 (en) 2005-06-29 2007-08-31 Lab Francais Du Fractionnement PROCESS FOR SEPARATING FIBRINOGEN PROTEINS, FACTOR XIII AND BIOLOGICAL GLUE OF SOLUBILIZED PLASMA FRONTION AND PREPARATION OF LYOPHILIZED CONCENTRATES OF SAID PROTEINS
HUE028626T2 (en) 2008-06-23 2016-12-28 Bio-Products & Bio-Engineering Ag Fibrinogen being funtionally intact , storage stable and virus-inactivated
CN106046147B (en) 2010-09-20 2019-11-19 欧克塔医药公司 Fibrinogen production method
AU2013231321B2 (en) * 2012-03-13 2017-05-25 Octapharma Ag Improved process for production of fibrinogen and fibrinogen produced thereby
US20140154233A1 (en) 2012-12-05 2014-06-05 Csl Limited Method of purifying therapeutic proteins
US10188965B2 (en) 2012-12-05 2019-01-29 Csl Behring Gmbh Hydrophobic charge induction chromatographic depletion of a protein from a solution

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2632309B1 (en) * 1988-06-07 1990-08-24 Lille Transfusion Sanguine PROCESS FOR THE CHROMATOGRAPHIC PURIFICATION OF PROTEINS, PARTICULARLY FACTOR VIII, AND THE PRODUCTS OBTAINED
FR2644064B1 (en) * 1989-02-17 1994-05-27 Aquitaine Dev Transf Sanguine PROCESS FOR THE MANUFACTURE OF THE FVIIIC ANTIHEMOPHILIC FACTOR HAVING VERY HIGH PURITY AND THE FVIIIC ANTIHEMOPHILIC FACTOR THUS OBTAINED, AS WELL AS THE PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
IT1248723B (en) * 1990-06-12 1995-01-26 Scalvo S P A PROCESS FOR THE PURIFICATION OF FACTOR VIII AND FACTOR VIII OBTAINED WITH SUCH PROCESS

Also Published As

Publication number Publication date
DE69303941T2 (en) 1997-03-27
FR2686883A1 (en) 1993-08-06
ES2049701T3 (en) 1997-01-16
EP0555135A1 (en) 1993-08-11
GR3021419T3 (en) 1997-01-31
FR2686883B1 (en) 1994-05-13
DE555135T1 (en) 1994-03-31
DE69303941D1 (en) 1996-09-19
EP0555135B1 (en) 1996-08-14
GR930300095T1 (en) 1993-09-30
ES2049701T1 (en) 1994-05-01
ATE141284T1 (en) 1996-08-15

Similar Documents

Publication Publication Date Title
US4673734A (en) Porous mineral support coated with an aminated polysaccharide polymer
ES2070919T5 (en) CHROMATOGRAPHIC SEPARATION OF PLASMA PROTEINS, MAINLY OF FACTOR VIII, OF THE WILLEBRAND FACTOR OF FIBRONECTINE AND FIBRINOGEN.
ATE179425T1 (en) METHOD FOR DEPRESENTATION OR REMOVAL OF ENDOTOXINS
EP0121976A3 (en) Partially purified osteogenic factor and process for preparing same from demineralized bone or an osteosarcoma
NZ509135A (en) A third generation intravenous immunoglobulin G (IVIG) purified using column chromatographic ion exchange methods
DK0576294T3 (en) Chondroitinase, Method of Preparation of Chondroitinase and Pharmaceutical Composition Containing Chondroitinase
CA2058676C (en) Process for isolating human albumin from supernatant iv, in particular iv-4, or from cohn's fraction v or from an analogous supernatant or fraction
DE69637509D1 (en) PROCESS FOR CLEANING FACTOR IX
DK0555135T3 (en) Process for the preparation of very high purity fibrinogen, thus produced very high purity fibrinogen, and a pharmaceutical composition containing it
CA1133898A (en) Purification of interferon
DK0659767T3 (en) Process for Preparation of a Concentrate of Anti-D-Immunoglobulin G and a Pharmaceutical Composition Containing It
ATA82786A (en) METHOD FOR SEPARATING PROTEINS BY MEANS OF GRADIENT ELUTION AND DEVICE FOR IMPLEMENTING THE METHOD
FR2585708B1 (en) RESIN AND ACID PROTEIN INHIBITOR AMINOALCOHOL DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC APPLICATION THEREOF
US4677197A (en) Purification method for tumor necrosis factor
DK1062244T3 (en) Improved Methods for Preparation of Factor VIII Proteins
WO1996016084A3 (en) A method of identifying cftr-binding compounds useful for activating chloride conductance in animal cells
KR960023066A (en) Method for purifying non-hepatitis (B) hepatitis surface antigen containing bis (S) 2 peptide
DE3788170D1 (en) Method of purifying and isolating two ionic forms of somatomedin.
RU2148411C1 (en) Method of preparing virus-inactivated factor viii-containing fraction by chromatography methods
ATE528393T1 (en) METHOD FOR PURIFYING PROTEIN AND GLUCOSE DEHYDROGENASE
EP0868507B1 (en) Process for the purification of urease from helicobacter pylori
EP0179485A2 (en) A process for the purification of HBsAg
DE58902637D1 (en) METHOD FOR THE AFFINITY CHROMATOGRAPHIC CLEANING OF FACTOR XIII.
ATE175214T1 (en) METHOD FOR SEPARATING GLYCOSYLATED AND UNGLYCOSYLATED PROTEINS
JPH038196B2 (en)